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Implementing an arts-based intervention
for patients with end-stage kidney disease
whilst receiving haemodialysis: a feasibility
study protocol
Claire Carswell1* , Joanne Reid1, Ian Walsh2, Helen McAneney2 and Helen Noble1
Abstract
Background: End-stage kidney disease is a life-changing illness. Many patients require haemodialysis, a treatment
that impacts profoundly on quality of life and mental health. Arts-based interventions have been used in other
healthcare settings to improve mental health and quality of life; therefore, they may help address the impact of
haemodialysis by improving these outcomes. However, there is a lack of evidence assessing their effectiveness in
this population and few randomised controlled trials (RCTs) evaluating the effectiveness of complex arts-based
interventions.
Methods: The aims of this study are to establish the feasibility of a cluster RCT of an arts-based intervention for
patients with end-stage kidney disease whilst receiving haemodialysis through a cluster randomised pilot study,
explore the acceptability of the intervention with a process evaluation and explore the feasibility of an economic
evaluation. The study will have three phases. The first phase consists of a cluster randomised pilot study to establish
recruitment, participation and retention rates. This will involve the recruitment of 30 participants who will be
randomly allocated through cluster randomisation according to shift pattern to experimental and control group.
The second phase will be a qualitative process evaluation to establish the acceptability of the intervention within a
clinical setting. This will involve semi-structured interviews with 13 patients and three focus groups with healthcare
professionals. The third phase will be a feasibility economic evaluation to establish the best methods for data
collection within a future cluster RCT.
Discussion: Arts-based interventions have been shown to improve quality of life in healthcare settings, but there is
a lack of evidence evaluating arts-based interventions for patients receiving haemodialysis. This study aims to assess
the feasibility of a future cluster RCT assessing the impact of an arts-based intervention on the wellbeing and
mental health of patients receiving haemodialysis and identify the key factors leading to successful implementation.
The hope is this study will inform a trial that can influence future healthcare policy by providing robust evidence
for arts-based interventions within the haemodialysis setting.
Trial registration: The trial was prospectively registered on clinicaltrials.gov on 14/8/2018, registration number
NCT03629496.
Keywords: Art, Feasibility studies, Kidney failure, chronic, Randomised controlled trials as topic, Renal dialysis
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Background
End-stage kidney disease is the final stage of chronic
kidney disease. It is defined by an estimated glomerular
filtration rate of < 15ml/min/1.73m2 [1]. The estimated
glomerular filtration rate is the estimated rate of fluid
filtration within the glomerulus of the kidney and is the
main physiological indicator of renal function. Patients
with end-stage kidney disease are poly-symptomatic and
experience difficult symptoms including fatigue, pruritus,
pain, nausea, sexual dysfunction and muscle weakness,
which can profoundly impact quality of life (QoL) [2]. The
main treatment modalities for end-stage kidney disease
are renal replacement therapies, such as haemodialysis.
Haemodialysis is a difficult and time-consuming treatment
that requires patients to attend hospital up to three times
a week for approximately 4 h each time. During treatment,
the patient is connected to a dialysing unit to filter their
blood and remove waste products and excess fluid,
replacing the role of the kidneys. Patients receiving
haemodialysis have lower health-related quality of life
(HRQoL) than the general population [3]. Lower HRQoL
is associated with increased morbidity and mortality in
patients on haemodialysis [4]. Patients receiving haemodi-
alysis also have higher rates of anxiety and depression,
with approximately 20–50% of the patient population
experiencing depression and/or anxiety [5–9].
Depression is an independent predictor of mortal-
ity in haemodialysis populations [10, 11]; depression
may result in poor treatment adherence [6, 12], mal-
adaptive health behaviours [13], self-harm and in-
creased suicide risk [14]. Management of end-stage
kidney disease involves an extensive and challenging
treatment regimen including compliance with dialysis
sessions, medications and fluid and diet restrictions
[6]. Non-adherence to such regimens can increase
mortality risk—missing a single dialysis session each
month increases risk of death by 30% [15]. Depres-
sion is a contributing factor to non-adherence for
patients receiving haemodialysis [12]. Anxiety can
also have an impact on the physical health of pa-
tients receiving haemodialysis, as anxiety symptoms
have a significant relationship with performance sta-
tus [16, 17]. Therefore, symptoms of both anxiety
and depression have a potential impact on the phys-
ical wellbeing of patients receiving haemodialysis.
Another collective relationship exists between HRQoL,
anxiety and depression in patients receiving haemodialy-
sis. A cross-sectional multi-centre study conducted in
Malaysia found that depression, anxiety and stress corre-
lated significantly with HRQoL [8]. Cohort studies
within the UK and Ireland also report this association
[3]. A systematic literature review found 100% of identi-
fied articles showed a statistically significant relationship
between anxiety, depression and HRQoL [18]. Clinical
depression influences QoL in varying ways, including
impacting mood and motivation [19, 20]. As previously
described, depression can lead to poor treatment adher-
ence [6], which increases symptom burden. Symptoms
experienced by patients with end-stage kidney disease
impact mood and increase depressive symptoms [21–
23]. The relationship between HRQoL, anxiety and
depression is enmeshed, yet anxiety and depression
remains underdiagnosed and under-treated in haemodi-
alysis patients [7, 24–26]. One reason for this complex
dynamic is the overlap between anxiety, depression and
the uremic state; many symptoms of depression and anx-
iety, such as anorexia, sleep disturbance and sexual
dysfunction, are identical to symptoms of uraemia, making
it difficult to differentiate anxiety or depression from the
clinical picture of end-stage kidney disease [5, 26]. Stigma
surrounding depression also contributes to diagnosis and
treatment rates, as patients are reluctant to agree to
psychiatric assessments [27]. HRQoL, anxiety and depres-
sion cannot, therefore, be considered in isolation from
each other when caring for patients with end-stage kidney
disease.
Arts-based interventions
The application of arts in health has received recent inter-
est because of its’ potential to improve patient outcomes
and reduce costs for the National Health Service (NHS)
[28]. Arts-based interventions involve the implementation
of arts activities in a healthcare context to deliver a cre-
ative experience [29]. They have been shown to improve
QoL, symptom burden and mental health [30–32] in a
variety of settings, including the medical-surgical setting
[32], primary care [33] and cancer care [34], although
there is a dearth of evidence exploring their effect in renal
populations. Research examining arts-based interventions
is small in scale [35], lacks longitudinal follow-up [36] and
focuses on receptive interventions such as music listening
[30, 31]. There are few studies examining the effect of
arts-based interventions in patients with end-stage kidney
disease; some studies have examined music listening in pa-
tients receiving haemodialysis [37], whilst others have
explored the use of arts-in-medicine programs. There is a
lack of consistent outcome measures in these studies, but
there is some evidence that arts-based interventions could
have a wide variety of beneficial effects, such as reducing
pain and other unpleasant symptoms [38, 39], improving
physiological parameters such as oxygen saturation and
respiratory rate [39–41], reducing anxiety [42], improving
HRQoL [43] and potentially improving biochemical values
such as albumin [43]. However, the research exploring
arts-in-medicine programs tends to be observational [43]
or exploratory [44, 45], and no randomised controlled trials
have been conducted on non-music listening interventions
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for patients with end-stage kidney disease receiving
haemodialysis.
To evaluate the effectiveness of arts-based interven-
tions, rigorous RCTs are necessary. However, there are
difficulties associated with RCTs in this arena, particu-
larly around participant recruitment and retention [46].
This is exacerbated in palliative care trials, where par-
ticipation rates under 50% are common [47] and trials
in nephrology also experience problems retaining par-
ticipants [48]. Methodology in arts-based intervention
research needs to be considered due to the lack of
RCTs conducted using non-music interventions [31,
36] and the tendency of complex interventions to fail to
demonstrate a statistically significant effect [49]. When
evaluating complex interventions, an assessment of the
intervention’s acceptability for patients and healthcare
professionals (HCPs) should be conducted [50]. To
explore the acceptability of an intervention, a process
evaluation must be conducted. Process evaluations pro-
vide an understanding of complex interventions by
examining their implementation, mechanism of impact
and context [51]. When exploring HCPs’ experiences of
arts-based interventions, it is also important to examine
the impact on HCPs themselves [31, 36]. This includes
consideration of potential negative effects of arts-based
interventions on the clinical working environment.
Arts-based interventions have potential to interfere
with work flow, increase stress and restrict communica-
tion between HCPs [52]. Any negative consequences
could impact patient safety; therefore, the acceptability
of an intervention for HCPs is important to consider
[53]. The acceptability of the intervention for patients
must also be considered. If an effective intervention is
burdensome, patients may not participate and not
experience any potential benefits [53].
There is also a need to consider arts-based interventions
from an economic perspective, as current guidance on re-
search into arts-based interventions recommends cost-ef-
fectiveness or cost-utility is evaluated [54], as the National
Institute for Health and Care Excellence (NICE) use
cost-effectiveness to inform recommendations for funding
healthcare interventions [55]. Whilst there is evidence that
suggests arts-based interventions can save the healthcare
system money (arts-on-prescription are thought the save
the NHS £216 per person) [35], there is a lack of formal
economic evaluations within the evidence base [56]. Conse-
quently, it is important to explore the best methods for
collecting the data needed for future analysis, to ensure that
a formal economic evaluation is feasible within an RCT.
Objectives
 To assess the feasibility of conducting a definitive
randomised controlled trial to evaluate the impact of
an arts-based intervention through a cluster ra
ndomised pilot study.
 To explore the acceptability of the implementation
of an arts-based intervention and randomised
controlled trial in a haemodialysis unit for both
patients and HCPs.
 To assess the feasibility of conducting a definitive
economic evaluation of an arts-based intervention
for patients receiving haemodialysis.
Methods
Research design
The study will consist of three phases and will utilise a
parallel mixed-method design. Phase 1 will involve a
quantitative cluster randomised pilot study, phase 2 is a
qualitative process evaluation and phase 3 is a feasibility
economic evaluation [57].
Research setting
The research will be conducted in an outpatient haemo-
dialysis unit of a teaching hospital in the Northern
Ireland. The unit provides haemodialysis to approxi-
mately 120 patients. Participants will be recruited from
the unit using convenience sampling.
Cluster randomised pilot study
Participants
Eligibility criteria for patients:
 Age 18 or over
 Able and willing to provide consent
 Receiving haemodialysis (both incident and
prevalent haemodialysis patients will be eligible)
There is little consensus on the appropriate sample
size for a feasibility study, with guidance ranging
from 12 per arm [58] to 50 per arm [59]. This guid-
ance reflects the inconsistent reporting of feasibility
studies. A review of pilot and feasibility studies con-
cluded studies were poorly reported and placed an
inappropriate emphasis on hypothesis testing [60].
National Institute of Health Research published
guidelines highlighting hypothesis testing is inappro-
priate in feasibility studies [61]; therefore, a power
calculation has not been conducted, as hypothesis
testing is not an objective of this trial. A sample size
of 30 is recommended by the National Institute for
Health Research (NIHR) [62] for parameter estima-
tion within an RCT. A university statistician con-
firmed that a sample of 30 was appropriate to satisfy
the research objectives.
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Recruitment
Eligible patients will be screened by a gatekeeper work-
ing in the haemodialysis unit. Screening logs will be used
to measure the proportion of patients who are eligible,
who are interested in participating and reasons for
non-participation [63]. Patients who are eligible will be
asked to consent to a first approach by the researcher,
who will describe the study and provide the patient with
a participant information sheet. The researcher will
allow each patient a period of 48 h to consider participa-
tion before providing a standardised consent form.
Randomisation
Participants will be randomly allocated to the control
group, receiving usual care, or the experimental group,
receiving usual care plus the arts-based intervention.
The control group will be asked not to participate in
visual art or creative writing during haemodialysis ses-
sions until data collection is complete. Once data col-
lection has been completed, the control group will
receive the same art materials as the intervention
group and a facilitated session of art activities whilst on
haemodialysis.
Cluster randomisation according to shift pattern
(Monday, Wednesday, Friday or Tuesday, Thursday,
Saturday) will be used, as this reduces the risk of
contamination of the control group. Any identified in-
stances of contamination or deviations from protocol,
such as patients attending different shifts and being
exposed to the intervention, will be documented in
order to inform the best randomisation strategy
within a definitive trial. Researchers will aim to re-
cruit an equal number of participants from each shift
to ensure both the control and experimental groups
contain an equal number of participants [64]. The
randomisation procedure will be carried out by a
member of staff within the university who is not affil-
iated with the study. They will toss a coin which will
determine what shift pattern will receive the interven-
tion. The allocation will be placed in a sealed enve-
lope that will be opened by the researcher once
baseline data collection has been completed.
Intervention
The intervention is based on the psychological theory
of flow, which posits the existence of a ‘flow state’, a
state of optimal experience that results from complete
absorption in a task. In order to induce a flow state,
the task must present a challenge to the individual
that they can overcome through the development of
their skills [65, 66]. Qualitative literature has sug-
gested arts-in-medicine programmes, person-centred
arts programmes that are delivered within hospitals,
can induce the hallmark experiences of a flow state in
patients who participate, such as an altered percep-
tion of time and reduction in rumination and anxiety
[43, 45, 67]. Therefore, the intervention has been
modelled on these programmes, with additional struc-
ture put in place to allow for assessment of dose and
fidelity.
The intervention consists of six 1-hourly art ses-
sions, implemented at the bedside whilst the partici-
pant is receiving haemodialysis and facilitated by the
researcher. Each participant will receive the sessions
over a course of 3 weeks, receiving two sessions a
week. This time frame was chosen in consultation
with the study’s interdisciplinary advisory group who
recommended each participant receive a day off each
week to reduce the potential of fatigue influencing
participation, in consultation with experts in the field
of arts in health who established six sessions was an
adequate dose [68], and reviewing previous literature
that identified 1 h is the optimal time frame for
implementing an art activity [69]. The activities on
offer will consist of a selection of discrete choices,
either creative writing and visual art, but will involve
a person-centred approach that will allow patients to
adapt the activities to their interests and their abil-
ities. This person-centred approach is modelled on
the arts-in-medicine programmes that have shown
evidence of being sustainable in clinical settings over
prolonged periods of time [43–45].
Each participant will receive their own individual
arts pack that will contain a standardised set of mate-
rials that were selected by the study’s interdisciplinary
advisory group. The items were selected according to
their ease of use and their ability to be implemented
without impacting the clinical setting. Each partici-
pant will receive:
 Sketch book
 Graphite pencils
 Graphic pens
 Watercolour paints
 Watercolour brush pen with in-built water container
 Colouring pencils
 Drawing board
 Drawing board clip
 Eraser
 Sharpener
 Pencil grip
Individual packs will be provided to each participant
to maintain infection control and reduce any issue of
cross-contamination between participants. All partici-
pants will keep the packs at the end of the study.
Each session will involve one to one facilitation to en-
sure the activities are accessible for the majority of
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patients, as arteriovenous fistulas and problems with
dexterity can limit a person’s ability to use the
materials unassisted. Patient preference of activity,
materials and engagement will be captured in activity
logs by the researcher implementing the intervention.
Data collection and management
Feasibility measures The primary outcome of the trial
will be the recruitment rate of participants within a
single site. Assessing the ability to recruit and retain par-
ticipants is a common issue explored in feasibility trials
and randomised pilot studies [60, 63, 70, 71]. Reasons
for non-participation will be collected in screening logs
during the recruitment phase. Previous experience with
art will be collected in these screening logs to explore
whether experience influences recruitment or retention
of participants.
Secondary outcomes include the attrition rate of
participants over a period of 3 months to assess the
feasibility of longitudinal follow-up within a definitive
trial. The acceptability of outcome measures will also
be assessed by completion rates of clinical outcome
measures, missing data, and will be further informed
by the parallel process evaluation.
Clinical outcome measures Baseline demographic and
clinical data will include age, gender, ethnicity, educa-
tion, dialysis vintage, frailty and co-morbidities; this will
be collected through self-report to establish any differ-
ences between control and experimental groups and to
identify any factors that may contribute to participation
or attrition within the trial.
Due to the wide variety of primary outcomes evalu-
ated in the existing evidence base, it is not clear what
the most appropriate primary clinical outcome meas-
ure is for a definitive trial; however, assessment of the
appropriateness of clinical outcome measures and
exploration of potential mechanisms of impact can be
explored during feasibility testing to ensure the most
relevant clinical outcomes are included in a definitive
trial [72]. The most consistently reported improve-
ment in the existing literature base is anxiety [73];
therefore, the Hospital Anxiety and Depression Scale
(HADS) will be used; this scale has been validated in
patients with end-stage kidney disease [74] and en-
ables exploration of both depression and anxiety inde-
pendently through a subscale analysis [75].
The Kidney Disease Quality of Life Short Form 36
(KDQoL-SF36) will be used to measure HRQoL; this is a
commonly used tool in renal literature, is both valid and
reliable and provides the most comprehensive overview
of contributing factors to QoL [76]. This questionnaire
was selected as it is the most comprehensive HRQoL
scale with the ability to explore different subscales [76],
and observational studies have suggested that arts-based
interventions may result in improvements in the
KDQoL-SF 36, improve physiological parameters and
help reduce unpleasant physical symptoms of the disease
[38, 39, 43, 77].
Arts-based intervention research faces criticism for
lack of longitudinal follow-up, which is necessary to
assess sustainability and lasting benefits [36]. Partici-
pants who are lost to follow-up in longitudinal RCTs
of complex interventions tend to be older, diagnosed
with a chronic illness and have higher co-morbidity
[78], common demographic factors in patients with
end-stage kidney disease [79]. Therefore, to establish
feasibility of longitudinal follow-up according to attri-
tion rates and assess the impact of participant burden,
clinical outcome measures will be collected at base-
line, immediately post-intervention, at 6 weeks and 3
months. The follow-up time points within this feasi-
bility study will allow exploration of reasons for attri-
tion and provide participants with an opportunity to
familiarise themselves with the outcome measures and
assess participant burden for further exploration
within the process evaluation.
The schedule for enrolment, administration of inter-
ventions and assessment of outcomes (including those
for phase 2 and 3) can be seen in Fig. 1.
Data analysis
Data analysis will be conducted using the Statistical
Package for the Social Sciences (SPSS v 24). Descriptive
statistics will be used to present baseline demographic
and clinical data. Categorical data will be presented as
frequencies and percentages, whilst continuous data will
be presented as means and standard deviations. Recruit-
ment, participation and retention rates will be reported
and presented in a CONSORT flow diagram [80]. The
proportion of patients who were eligible for recruitment,
who consented to participate and who completed the
study will be presented with 95% confidence intervals.
Exploratory inferential statistics will be conducted
to establish the time needed for data analysis and to
explore any potential effects from clustering at the
level of shift pattern, but no conclusions of effective-
ness of the intervention will be made. Differences in
baseline and demographic measures between the clus-
ters will be compared using analysis of variance
(ANOVA) for continuous data and χ2 for categorical
data to identify any unanticipated confounding vari-
ables introduced by clustering according to shift pat-
tern. As the study is not statistically powered, the
results will be interpreted with caution. Independent t
tests (or Mann-Whitney U) will be conducted to
compare the average scores of the experimental group
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and control group. The majority of arts-based inter-
vention research involves pre- and post-test designs;
therefore, a repeated measures t test (or Wilcoxon
matched pairs test) will also be conducted.
Process evaluation
Participants
Participants will include patients and HCPs. The patients
recruited will include those who either participated or
withdrew from the cluster randomised pilot study. HCPs
from the unit will also be recruited into the process
evaluation.
Eligibility criteria for HCPs:
 A member of the multidisciplinary healthcare team,
including nurses, healthcare support workers, doctors,
dietitians, social workers and counsellors who:
 Has had exposure to the intervention.
 Has worked in a renal setting for more than 3
months
Familiarity with the context of the clinical environ-
ment is needed to inform the acceptability of the inter-
vention [53]. Context includes the social system of the
work place, taking into consideration social norms and
material resources [53].
Recruitment
During the cluster randomised pilot study, patients
who have been recruited will be offered the oppor-
tunity to participate in the process evaluation. A sep-
arate information sheet and consent form will be
provided for this phase. Participants from both the
intervention and control group will be recruited, and
participants will be informed that participation in the
process evaluation is not dependent on completion of
the cluster randomised pilot study, so participants
Fig. 1 SPIRIT figure illustrating the schedule of enrolment for participants, implementation of interventions and timeline of assessments for phases 1, 2 and 3
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who decide to withdraw from the feasibility study can
be included in the sample.
HCPs will be recruited for the process evaluation
by purposive sampling. During the feasibility trial, the
researcher implementing the intervention will identify
HCPs who are present on the unit during implemen-
tation of the intervention. The unit manager, acting
as the gatekeeper, will screen the identified HCPs to
ensure they meet the inclusion criteria and it is
acceptable for the researcher to make the initial
approach. Due to managerial and social hierarchies
within hospitals, HCPs may feel pressure to partici-
pate; therefore, HCPs will be approached by the
researcher directly, so the gatekeeper will be unaware
of who is participating.
Data collection and management
Approximately 13 patients will be recruited into the
process evaluation. The principle of 10 + 3 for data
saturation outlines a minimum of 10 interviews
should be conducted, followed by at least three con-
secutive interviews that present no new findings [81].
Three focus groups will be conducted with five HCPs
per focus group [82, 83]. The dialysis unit in which
the study is taking place is small, so the focus group
size will be limited by the HCPs available [84, 85].
Data collection will continue until data saturation is
reached.
Data collection for the qualitative process evaluation
will occur parallel to the cluster randomised pilot
study, as this allows adaptation of the intervention to
identified concerns during the feasibility stage, as rec-
ommended by the Medical Research Council (MRC)
guidance [50]. The semi-structured interviews will be
conducted with patients in their own home to avoid
the power dynamic present in a clinical setting [86].
This approach will be flexible and patients can
request a different location. The focus groups with
HCPs will take place in a location convenient for all
participants. The process evaluation will follow MRC
guidance [50] and will focus on the acceptability of
the intervention for patients and HCPs, and the
interview guides will be informed by the RE-AIM
QuEST framework [87]. The interview guide for the
semi-structured interviews for patients and focus
groups for HCPs can be found in Additional file 1.
Data analysis
The semi-structured interviews and focus groups will be
conducted by the same researcher and recorded and tran-
scribed verbatim. Inductive thematic analysis will be used to
analyse the data collected. Thematic analysis involves iden-
tifying and coding central themes within qualitative data
through an iterative process [88]. Investigator triangulation
will be used to ensure validity of the identified themes [89].
Economic evaluation
Data collection and management
Feasibility studies are not adequately powered to estab-
lish effectiveness; therefore, conducting a cost-utility
evaluation is not appropriate [90]. However, the feasibil-
ity of data collection methods and appropriateness of
outcome measures will be evaluated during feasibility
testing to inform an economic evaluation within a
definitive RCT.
Health and social care costs of participants will be
collected using a Patient Service Use Log, a prospect-
ive log that captures information on participants
healthcare resource use during their time in the study
[91]. These will be provided to participants during
baseline data collection of the cluster randomised
pilot study and collected during follow-up, post-inter-
vention and at 6 weeks and 3 months by the
researcher. The outcome of interest is the completion
rate for the Patient Service Use Log. The EQ-5D-5 L
will be administered to patients in conjunction with
clinical outcome measures, pre-/post-intervention and
at 6 weeks and 3 months follow-up. The outcome of
interest is the acceptability of the EQ-5D-5 L for use
within an economic evaluation, as determined by
completion rates, missing data and assessment within
the process evaluation. The EQ-5D-5 L is recom-
mended by NICE for deriving utility values for the
calculation of quality-adjusted life years in economic
evaluations [92]. Whilst it is not anticipated that
arts-based interventions can improve all items of the
EQ-5D-5 L, there is evidence that suggests they may
help patients manage pain [38], improve dexterity
[93], reduce depression and anxiety [94] and subse-
quently improves motivation and engagement in daily
activities [31, 95, 96].
Data analysis
A cost-consequence analysis is recommended by the
NIHR for feasibility studies [97]. Costs and outcome
measures will be presented using descriptive statistics,
including means and 95% confidence intervals to show a
general overview of the economic consequences of the
intervention. Completion rates and missing data for the
Patient Service Use Log and the EQ-5D-5 L will be pre-
sented as frequencies to assess the feasibility of data
collection.
Progression criteria
Progression to a definitive RCT will be determined by
recruitment rates [98] and the acceptability of the inter-
vention for patients and staff. Acceptability will be
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evaluated through the qualitative process evaluation, as
it is recommended that both quantitative and qualitative
data are used when determining the feasibility of a ran-
domised controlled trial [50, 72]:
 75–100% of the target sample size recruited from a
single site will result in progression to a definitive
RCT.
 50–74% of the target sample size recruited from a
single site will result in progression to a definitive
trial after reviewing the protocol and data from the
process evaluation, and making appropriate
amendments to address barriers to recruitment.
 25–49% of the target sample size recruited from a
single site will result in progression to a definitive
trial after reviewing the protocol with input from
potential co-applicants to ensure that the protocol is
modified to enhance recruitment rates.
 Less than 25% of the target sample size recruited
from a single site will probably result in the trial not
progressing, unless a significant modifiable barrier is
identified within the process evaluation.
 More than 20% attrition rate [99] from the recruited
sample will result in revision of the protocol and
data from the process evaluation, and appropriate
amendments will need to be made to address
barriers to retention of participants, prior to
progression to a full trial.
 Progression to a full trial will be contingent on the
acceptability of the intervention for both patients
and HCPs regardless of recruitment rates. This will
be explored within the qualitative process evaluation
[87]. Any necessary modifications identified will be
made prior to progression to a definitive trial.
 The use of the outcome measures in a definitive trial
will be contingent on the acceptability of the
questionnaires, which will be informed by
completion rates and through the qualitative process
evaluation. Any necessary modifications, such as
removing questionnaires or using only certain
subscales, will be made prior to progression to a
definitive trial.
Discussion
Whilst patients with end-stage kidney disease receiving
haemodialysis may stand to benefit from arts-based
interventions, the lack of RCTs limits the ability of the
evidence base to influence healthcare policy and enable
access to these interventions. Arts-based interventions
also constitute a complex intervention according to
MRC guidance, and therefore, additional factors outside
of efficacy, including the context of implementation,
acceptability for patients and acceptability for HCPs, also
need to be considered to inform optimal strategies for
implementation in clinical practice. This article has out-
lined a protocol to develop an arts-based intervention
for patients with end-stage kidney disease whilst receiv-
ing haemodialysis and to assess the feasibility of a paral-
lel cluster randomised controlled trial and economic
evaluation. This study will provide a foundation from
which a definitive RCT protocol can be developed that
can assess the effectiveness of highly complex arts-based
interventions for patients with end-stage kidney disease
receiving haemodialysis, within a framework that can be
used to inform healthcare policy.
Limitations
One limitation of this protocol is the lack of differentiation
of roles. As a consequence of limited resources, the devel-
opment of the intervention, the implementation of the
intervention, data collection and data analysis will be con-
ducted by a single research team. Ideally, these roles would
be distinct and performed by separate teams, as outlined
in the MRC guidelines [50]. Any future definitive trial
should have separate teams implementing the interven-
tion, collecting the quantitative data and collecting the
qualitative data for a process evaluation to reduce the risk
of bias. It is also recommended that in any future process
evaluation, multiple team members should transcribe and
thematically analyse qualitative data. Another limitation is
the lack of attention placebo provided to the control group
[100]; whilst no hypothesis testing is being conducted to
establish the efficacy of the intervention, attention placebo
control may influence retention of participants in the com-
parator group. Implementation of two different interven-
tions is not feasible within the restricted resources of this
study; however, the process evaluation may help inform
the elements needed in a future attention placebo control
group within a definitive RCT. An additional consideration
that will inform a definitive RCT is the need for multiple
clusters to control for between-cluster variation. Whilst
the size of this study restricted randomisation to only two
clusters, a definitive trial will likely require multiple sites
to ensure an adequate number of clusters.
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